Key facts
- H.C. Wainwright reiterated its rating on Axsome stock.
- The reiteration followed Axsome's resolution of patent disputes for Sunosi.
- The settlement removes legal uncertainty for the narcolepsy drug.
H.C. Wainwright has reiterated its rating on Axsome Therapeutics stock subsequent to the company's announcement that it has resolved all patent disputes concerning its narcolepsy drug, Sunosi. The analyst firm's reiteration centered on the details of the patent settlement and its potential implications for Axsome's stock performance. The resolution of these disputes removes legal uncertainty surrounding Sunosi's intellectual property and market exclusivity.